New treatments for multidrug-resistant non-fermenting Gram-negative bacilli Infections

Rev Esp Quimioter. 2022 Oct;35 Suppl 3(Suppl 3):51-53. doi: 10.37201/req/s03.12.2022. Epub 2022 Oct 24.

Abstract

Ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol belong to a novel generation of antibiotics that correspond with the β-lactam family. It is necessary to having new options in treating infections caused by Gram-negative, non-fermenting multidrug-resistant bacilli due to the significant increase in multidrug resistance in the last decades. Knowing the main characteristics of each drug is key for correct use.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Ceftazidime* / pharmacology
  • Ceftazidime* / therapeutic use
  • Cephalosporins / pharmacology
  • Cephalosporins / therapeutic use
  • Drug Combinations
  • Drug Resistance, Multiple, Bacterial
  • Gram-Negative Bacteria
  • Gram-Negative Bacterial Infections* / drug therapy
  • Humans
  • Microbial Sensitivity Tests
  • Pseudomonas aeruginosa
  • Tazobactam / pharmacology
  • Tazobactam / therapeutic use

Substances

  • Ceftazidime
  • Cephalosporins
  • Tazobactam
  • Anti-Bacterial Agents
  • Drug Combinations